Completed PHASE1 INTERVENTIONAL 2-arm NCT01066754

Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fasting Conditions

Sponsor: Dr. Reddy's Laboratories Limited

Conditions Healthy

Interventions Fexofenadine

Updated 5 times since 2017 Last updated: Feb 9, 2010 Started: Apr 30, 2002 Primary completion: May 31, 2002 Completion: May 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01066754, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Dr. Reddy's Laboratories Limited, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Reddy's Laboratories Limited

Data source: Dr. Reddy's Laboratories Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sainte-Foy Quebec, Canada